Can a Foreigner Start Business in Switzerland?

Switzerland’s stable economy and global reputation for trust make it an appealing base for entrepreneurs. But for non-residents, starting a business here often comes with a learning curve. That hasn’t stopped a growing number of foreign founders – including those in immune cell therapy and novel cancer treatment – from setting up shop, especially as clinical trial activity continues to grow across Europe.

“There’s strong demand among international investors for access to the Swiss research ecosystem,” said one of our consultants. “It’s not just about location – it’s about credibility and infrastructure. And right now, Switzerland has both.”

How Foreigners Are Starting Swiss Companies

Non-residents – including those outside the EU – can legally own and operate a business in Switzerland. There’s no requirement to be physically present, but there are a few non-negotiables. A Swiss legal address is one. Having a local representative is another.

Typically, companies register as either a GmbH (a private limited company) or an AG (a public limited company). Both require starting capital – CHF 20,000 for the former, CHF 100,000 for the latter. Once that’s in place, the business must be recorded in the country’s Commercial Registry.

But beyond the paperwork, there’s a key legal condition. At least one board member or authorized representative must reside in Switzerland. For many foreign-led firms, this becomes the first major obstacle.

“That part tends to slow people down,” one of our consultants said. “But in fields like biotech, clinical research, or cancer therapy development, there are legal teams that regularly offer representation services to help startups comply. They know what’s needed to get things running without unnecessary friction.”

Why Health Innovators Choose Switzerland

For firms advancing experimental cancer treatment – including those working on Engineered Immune Enhancement (EIE) – having a Swiss base can open the door to a larger research and clinical network.

One of our specialists, who advises early-stage medical ventures, said the location brings advantages that go beyond funding. “Switzerland is seen as a gateway,” he explained. “Companies doing clinical trial therapy or immune cell therapy want proximity to regulators, hospitals, and research institutions. And they want to be taken seriously.”

Over the last year, several firms piloting EIE protocols have chosen to anchor clinical operations in cantons like Vaud or Basel, citing efficient approval timelines and access to trial-ready talent. Even firms headquartered abroad are establishing Swiss subsidiaries to run studies or secure early regulatory conversations.

Cost and Administrative Realities

While formation is relatively fast – often taking less than a month – the operational costs are not trivial. Swiss labor protections, mandatory insurance contributions, and real estate prices make it one of the more expensive markets in Europe to launch a company.

Still, Switzerland remains attractive thanks to a combination of benefits that appeal to foreign founders.

1. Strong intellectual property protections.
2. Predictable, stable legal framework.
3. Proximity to EU regulators and markets.
4. Availability of multilingual, highly educated workforce.
5. Opportunities for biotech-specific tax relief in some cantons.

That said, not every canton treats startups the same. Some, like Zug and Neuchael, have rolled out favorable tax policies or startup support programs aimed at attracting foreign innovation. Companies in R&D-heavy sectors, particularly those exploring immune cell-based therapies or oncology-related treatments, may also qualify for incentives or partial tax relief.

Still, there’s no “startup visa” in the traditional sense. For foreign founders hoping to live in Switzerland, a separate permit application is required – and typically, that hinges on showing clear economic value and a commitment to hiring locally.

Clinical Trials Are Driving New Entries

Switzerland’s role in global clinical development is expanding, and that’s helping attract foreign-led projects. EIE treatment – which engineers a patient’s own immune cells to recognize and attack cancer – is among the latest technologies being explored in Swiss labs. While still in early stages, its promise across multiple tumor types has sparked interest from both startups and major pharmaceutical firms.

One U.S.-based biotech developing T-cell therapies recently opened a Zurich office to oversee its trial portfolio across the EU. Another company out of Seoul registered a Swiss branch to coordinate EIE-based clinical trial therapy targeting gastrointestinal cancers.

These moves aren’t just symbolic. They signal where regulators, funders, and research partners expect breakthroughs to happen – and who they’re willing to work with.

What Founders Should Consider First

Before committing to a launch, foreign business owners are urged to weigh a few important factors. Not every sector is equally regulated. Not every canton offers the same tax structure. And not every investor will value a Swiss office the same way.

But for those in healthcare – particularly those navigating the long road of novel cancer treatment development – Switzerland remains a standout. Not just because of its reputation, but because it offers the infrastructure needed to do serious work.

If you’re exploring opportunities in Swiss biotech, looking to start a company in the clinical research space, or need support navigating regulatory and residency hurdles, our team works with founders worldwide to help build strategic, compliant operations in Switzerland.